{"filing":{"accession_number":"0001493152-26-026364","cik":"0000890821","ticker":"ENVB","company_name":"Enveric Biosciences, Inc.","form":"8-K","filing_date":"2026-05-29","report_date":null,"primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/890821/000149315226026364/form8-k.htm"},"events":[{"id":8212,"run_id":7203,"accession_number":"0001493152-26-026364","anchor_item_number":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.85,"summary":"The filing's primary substantive disclosure is Item 5.07, which reports the results of the 2026 Annual Meeting of Stockholders held on May 28, 2026. The filing details voting outcomes on six director elections, a say-on-pay proposal, a reverse stock split proposal, an authorized stock increase proposal, and auditor ratification. While Item 5.02 addresses new RSU and RSA award agreement forms (an executive compensation matter), the bulk of the 8-K content and materiality centers on the shareholder vote results, particularly the failed Authorized Stock Increase Proposal (427,158 for vs. 555,147 against), which would be material to investors assessing the company's capital structure flexibility.","company_name":"Enveric Biosciences, Inc.","ticker":"ENVB","filing_date":"2026-05-29","form":"8-K","submitted_at":null,"items":null}],"classifications":[{"id":2841,"accession_number":"0001493152-26-026364","item_number":null,"item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The filing's primary substantive disclosure is Item 5.07, which reports the results of the 2026 Annual Meeting of Stockholders held on May 28, 2026. The filing details voting outcomes on six director elections, a say-on-pay proposal, a reverse stock split proposal, an authorized stock increase proposal, and auditor ratification. While Item 5.02 addresses new RSU and RSA award agreement forms (an executive compensation matter), the bulk of the 8-K content and materiality centers on the shareholder vote results, particularly the failed Authorized Stock Increase Proposal (427,158 for vs. 555,147 against), which would be material to investors assessing the company's capital structure flexibility.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-30T02:36:48.112577+00:00","company_name":"Enveric Biosciences, Inc.","ticker":"ENVB","filing_date":"2026-05-29"}]}